Insider Selling: Athira Pharma (NASDAQ:LONA) CEO Sells $27,687.72 in Stock

Athira Pharma, Inc. (NASDAQ:LONA) CEO Mark James Litton sold 5,156 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $5.37, for a total transaction of $27,687.72. Following the sale, the chief executive officer directly owned 57,926 shares of the company’s stock, valued at approximately $311,062.62. This represents a 8.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Athira Pharma Stock Performance

LONA opened at $5.30 on Friday. The company has a market capitalization of $20.88 million, a price-to-earnings ratio of -0.55 and a beta of 2.68. Athira Pharma, Inc. has a 1-year low of $2.20 and a 1-year high of $8.36.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LONA. Wall Street Zen cut Athira Pharma from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Cantor Fitzgerald began coverage on Athira Pharma in a research report on Thursday, February 26th. They issued an “overweight” rating for the company. Zacks Research raised Athira Pharma to a “hold” rating in a research note on Friday, February 27th. Weiss Ratings initiated coverage on Athira Pharma in a research report on Wednesday, February 11th. They set a “sell (d-)” rating on the stock. Finally, Mizuho upgraded Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 price objective for the company in a research note on Thursday, February 19th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $10.00.

About Athira Pharma

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.